Authors
Natalia Espinola, Constanza Silvestrini, Carla Colaci, Soledad Monges, Natalie Soto, María José Varco, Fernando Argento, Andrés Pichon-Riviere
Published in
Value in health regional issues. Pages 102157. Nov 04, 2026. Epub Nov 04, 2026.
Abstract
Spinal muscular atrophy (SMA) is a genetic condition in which severe cases often lead to death before 2 years of age if untreated. Early diagnosis and intervention can substantially improve health outcomes. This study evaluates the cost-effectiveness of implementing newborn screening (NBS) for SMA compared with no screening in Argentina.
A cost-utility model was performed to evaluate the implementation of NBS for SMA compared with no screening. The model consisted of a decision tree to assess initial outcomes and a Markov model to simulate the short- and long-term effectiveness of SMA treatments. The analysis was conducted for a hypothetical annual birth cohort of 529 794 newborns from the perspective of the Argentine health system, integrating data from international literature, local sources, and expert opinion. Costs were estimated in Argentine pesos and converted to international US$ using 2024 World Bank purchasing power parity rates.
Base-case analysis estimated that for the modeled annual birth cohort, introducing NBS would yield a lifetime gain of 360 quality-adjusted life-years (QALYs) at an incremental cost of US$ 7 746 715. This corresponds to an incremental cost-effectiveness ratio of US$ 21 542 per QALY gained compared with no NBS, a value above the cost-effectiveness threshold of US$ 20 123 per QALY but below twice this threshold, which could be a reference for rare diseases.
NBS for SMA significantly improves health outcomes and could represent a cost-effective strategy for the Argentine health system.
PMID:
42980622
Bibliographic data and abstract were imported from PubMed on 04 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 10
- Comments 0